Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 3,750 Shares of Stock

Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. sold 3,750 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $127.54, for a total transaction of $478,275.00. Following the completion of the sale, the vice president now owns 19,608 shares in the company, valued at approximately $2,500,804.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Thursday, December 28th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock. The shares were sold at an average price of $114.08, for a total transaction of $604,624.00.
  • On Thursday, December 28th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock. The shares were sold at an average price of $114.08, for a total transaction of $604,624.00.
  • On Wednesday, November 29th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock. The shares were sold at an average price of $116.45, for a total transaction of $617,185.00.

Shares of Edwards Lifesciences Corp (EW) opened at $130.21 on Thursday. The firm has a market cap of $26,949.79, a P/E ratio of 33.51, a P/E/G ratio of 1.88 and a beta of 0.63. Edwards Lifesciences Corp has a 1-year low of $89.20 and a 1-year high of $138.48. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.15.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.03. The firm had revenue of $888.50 million during the quarter, compared to analysts’ expectations of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. The firm’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period last year, the firm posted $0.75 earnings per share. equities research analysts predict that Edwards Lifesciences Corp will post 4.49 EPS for the current fiscal year.

Edwards Lifesciences announced that its Board of Directors has authorized a share buyback program on Thursday, December 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Large investors have recently modified their holdings of the stock. Cerebellum GP LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth approximately $128,000. Resources Investment Advisors Inc. boosted its stake in Edwards Lifesciences by 66.0% in the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock worth $132,000 after purchasing an additional 465 shares during the period. Exane Derivatives boosted its stake in Edwards Lifesciences by 381.3% in the 4th quarter. Exane Derivatives now owns 1,213 shares of the medical research company’s stock worth $137,000 after purchasing an additional 961 shares during the period. MPS Loria Financial Planners LLC acquired a new position in Edwards Lifesciences in the 2nd quarter worth approximately $140,000. Finally, Dupont Capital Management Corp acquired a new position in Edwards Lifesciences in the 3rd quarter worth approximately $142,000. Hedge funds and other institutional investors own 81.11% of the company’s stock.

A number of research firms recently commented on EW. JMP Securities raised their price objective on shares of Edwards Lifesciences from $135.00 to $140.00 and gave the company a “market outperform” rating in a research note on Friday, February 2nd. SunTrust Banks reiterated a “buy” rating and set a $150.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, January 31st. Guggenheim reiterated a “buy” rating and set a $162.00 price objective on shares of Edwards Lifesciences in a research note on Friday, February 2nd. Barclays lowered their price objective on shares of Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 25th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $137.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, November 29th. Three investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Edwards Lifesciences currently has a consensus rating of “Buy” and an average price target of $141.15.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 3,750 Shares of Stock” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/02/15/insider-selling-edwards-lifesciences-corp-ew-vp-sells-3750-shares-of-stock.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply